Levetiracetam Jubilant

Levetiracetam, the active ingredient in Levetiracetam Jubilant, is an anticonvulsant presented as an oral tablet for oral use. It is prescribed to manage various seizure types in patients with epilepsy, including partial, generalized tonic‑clonic, and myoclonic seizures.

GNH USA supplies Levetiracetam Jubilant as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to European Union quality standards and provides reliable sourcing for bulk and unit‑dose requirements across global markets. Customers benefit from consistent product integrity, regulatory documentation, and responsive technical support.

Levetiracetam is an antiepileptic drug that reduces neuronal excitability and is indicated for several seizure types. - Partial seizures: helps control focal onset seizures, reducing frequency and severity. - Generalized tonic-clonic seizures: provides seizure control in patients with bilateral convulsive episodes. - Myoclonic seizures: diminishes rapid, brief muscle jerks associated with myoclonic epilepsy.

Levetiracetam may be associated with a range of adverse reactions, which vary in frequency and severity.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Somnolence: increased sleepiness or fatigue. - Headache: mild to moderate cranial pain. - Irritability: mood changes or agitation. - Nausea: upset stomach, sometimes with vomiting. - Nasal congestion: mild upper‑respiratory discomfort.

Serious or Rare Side Effects: - Severe skin reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Psychiatric disturbances: depression, suicidal thoughts, or aggressive behavior. - Hematologic abnormalities: thrombocytopenia or leukopenia. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Allergic reactions: anaphylaxis or angioedema.

When prescribing Levetiracetam, clinicians should consider several precautionary measures to ensure safe use. - Renal impairment: adjust dose in patients with reduced kidney function. - History of psychiatric illness: monitor for mood changes or suicidal ideation. - Concomitant CNS depressants: use caution as additive sedation may occur. - Pregnancy: risk unknown; weigh benefits against potential fetal exposure. - Elderly patients: start at lower dose and titrate slowly due to altered pharmacokinetics. - Store at ambient temperature: keep below 25 °C, in original container, protected from moisture and light.

Levetiracetam can interact with other medicines, influencing its effectiveness or safety profile.

Major Interactions (Avoid): - Carbamazepine: may reduce levetiracetam plasma levels, decreasing seizure control. - Phenobarbital: can lower levetiracetam concentrations, potentially compromising efficacy.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels, requiring dose adjustment. - Other antiepileptic drugs (e.g., phenytoin, lamotrigine): monitor for additive CNS effects. - Oral contraceptives: levetiracetam may slightly reduce hormonal efficacy; consider alternative contraception. - Alcohol: combined use can enhance sedation and dizziness.